When referencing the corporate and manufacturing footprint of Barostim, the device is developed and managed by CVRx, Inc., which maintains its primary corporate headquarters and executive operations in Minneapolis, Minnesota, United States. Geographically, the therapy itself is implanted in patients via specialized surgical procedures performed at certified medical centers, university hospitals, and advanced heart failure clinics across the United States and international markets like Germany, where trained electrophysiologists and cardiothoracic surgeons execute the procedures.